









Markets
/
Stocks
/
nasdaq-pcsa
/

Processa Pharmaceuticals Inc

PCSA

2.380USD

+0.210+9.68%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

5.03MMarket Cap

LossP/E TTM



Processa Pharmaceuticals Inc

2.380

+0.210+9.68%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Processa Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Processa Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 175 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Processa Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

175 / 392

Overall Ranking

329 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Processa Pharmaceuticals Inc Highlights

StrengthsRisks

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.

Fairly Valued

The company’s latest PE is -0.08, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 95.53K shares, increasing 40.67% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 23.59K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.85.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

25.000

Target Price

+1052.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Processa Pharmaceuticals Inc is 7.06, ranking 163 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.06

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Processa Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Processa Pharmaceuticals Inc is 6.51, ranking 263 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.08, which is -93.97% below the recent high of -0.01 and -18322.92% above the recent low of -15.27.

Score

Industry at a Glance

Previous score

6.51

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 175/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Processa Pharmaceuticals Inc is 7.00, ranking 311 out of 392 in the Biotechnology & Medical Research industry. The average price target is 1.00, with a high of 1.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

25.000

Target Price

+1052.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Processa Pharmaceuticals Inc

PCSA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Processa Pharmaceuticals Inc is 5.40, ranking 317 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.44 and the support level at 1.69, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.24

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.030

Sell

RSI(14)

35.236

Neutral

STOCH(KDJ)(9,3,3)

19.666

Neutral

ATR(14)

0.273

Low Volatility

CCI(14)

-112.658

Sell

Williams %R

76.923

Sell

TRIX(12,20)

-1.625

Sell

StochRSI(14)

97.417

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.399

Sell

MA10

2.760

Sell

MA20

3.041

Sell

MA50

4.188

Sell

MA100

5.265

Sell

MA200

2.751

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Processa Pharmaceuticals Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.22%, representing a quarter-over-quarter increase of 275.77%. The largest institutional shareholder is The Vanguard, holding a total of 23.59K shares, representing 1.04% of shares outstanding, with 124.50% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

HX Entertainment Ltd

218.69K

Stonepine Capital Management, LLC

41.21K

The Vanguard Group, Inc.

Star Investors

11.53K

+1079.94%

Geode Capital Management, L.L.C.

12.13K

+499.70%

Young (David)

9.45K

+5.32%

Lin (Patrick)

4.16K

+10.26%

Ng (George K)

4.29K

-28.91%

Yorke (Justin W)

2.14K

CorLyst, L.L.C.

1.66K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Processa Pharmaceuticals Inc is 1.04, ranking 352 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.